• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Allurion Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance

    3/21/24 8:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care
    Get the next $ALUR alert in real time by email

    Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion"), a company dedicated to ending obesity, today reported financial results for the fourth quarter and full year ended December 31, 2023, and reiterated 2024 guidance.

    Fourth Quarter Highlights and Outlook

    • Reiterating 2024 guidance on procedural volume, revenue, gross margin, and cash burn
    • Fourth quarter revenue of $8.2 million and full year 2023 revenue of $53.5 million, consistent with preannouncement on January 8
    • Procedural volume, as estimated through new app users, increased by 30% over 2022, reflecting robust demand for the Allurion Program
    • Completed enrollment in the AUDACITY pivotal trial ahead of schedule, a critical milestone for the premarket approval (PMA) application for the Allurion Balloon to the U.S. Food and Drug Administration (FDA)
    • Conducted research on 172 healthcare professionals and 1,663 patients that demonstrated a positive impact of GLP-1s and other anti-obesity medications on the awareness of the Allurion Program
    • Treated the first patients with the Allurion Balloon who were fully reimbursed by the UK NHS
    • Implemented a strategic cost reduction effort expected to reduce cash burn to approximately $30 million in 2024

    "Despite our fourth quarter being impacted by macroeconomic conditions and the surge of attention paid to GLP-1 drugs, over the course of 2023, we saw strong procedural volume growth, which we believe demonstrates robust underlying consumer demand for the Allurion Program," said Shantanu Gaur, Chief Executive Officer. "As we begin 2024, this demand has continued to increase, and we have seen improvement in some of the macro conditions that negatively impacted the fourth quarter. To take advantage of this, we have also taken meaningful steps to reduce our expense structure and provide increased operational flexibility.

    "As we look ahead, we are excited by the considerable attention the weight management space has received and the significant growth in overall market opportunity we believe this presents Allurion," continued Gaur. "Whether used in combination with a GLP-1 drug or as an alternative, we believe, and our research indicates, the Allurion Program benefits from this heightened market attention and provides a more comprehensive solution for the more than one billion people suffering from obesity globally."

    Fourth Quarter 2023 Financial Results

    Total revenue for the quarter ended December 31, 2023, was $8.2 million compared to $19.2 million for the same period in 2022. This reflected macroeconomic headwinds in certain markets leading to lower re-order rates during the period as distributors and accounts in certain markets adjusted their inventory levels and we reduced or paused sales to certain accounts to manage credit risk.

    Gross profit for the fourth quarter was 78% of revenue, compared to 79% of revenue in the same period in 2022.

    Sales and marketing expenses for the fourth quarter decreased $4.2 million to $10.7 million, compared to $14.9 million in the same period in 2022, driven largely by strategic reductions in spending to reduce cash burn and improve operational flexibility.

    Research and development expenses increased by $339 thousand to $6.1 million in the quarter.

    General and administrative expenses increased by $10.7 million to $15.4 million, compared to $4.7 million in the same period in 2022. The increase was driven by $7 million in accounts receivable reserves and $3 million in stock-based compensation expense and public company costs.

    Loss from Operations for the fourth quarter increased by $15.6 million to $25.7 million, compared to $10.1 million in the same period in 2022. The increase in Loss from Operations was driven by $8.8 million less gross profit due to lower revenue and increased operating expenses of $6.8 million.

    As of December 31, 2023, cash and cash equivalents totaled $38 million, an increase of $30.4 million from December 31, 2022, which includes the impact of Allurion's completed business combination with Compute Heath and partial paydown of existing debt.

    2024 Financial Outlook

    For full year 2024, Allurion reiterates the financial guidance it previously published:

    • Anticipated procedural volumes growth of 20%, reflecting increased penetration in key direct markets and reallocation of marketing spend to more efficient channels
    • Revenue of $60 to $65 million, reflecting 12-22% growth year-over-year
    • Expected gross margins of 77-79%, reflecting durable pricing of our gastric balloon as well as initial commercialization efforts for the Allurion Virtual Care Suite SaaS product
    • Targeted cash burn of approximately $30 million for the full year

    Conference Call and Webcast Details

    Allurion management will host a conference call at 8:30 a.m. ET today, March 21, 2024. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 646 960 0804 (international) and use Conference ID 1905455. To listen to the conference call via live audio webcast, please visit the Events section of Allurion's Investor Relations website at Allurion - Events & Presentations.

    A replay of the conference call will be available by telephone by dialing (800) 770 2030 (domestic) or +1 647 362 9199 (international) and using Access Code 1905455. The archived webcast will also be available on Allurion's Investor Relations website mentioned above.

    About Allurion

    Allurion is dedicated to ending obesity. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world's first and only swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan, whether it is gastric balloon, surgical, medical or nutritional. The Allurion Gastric Balloon is an investigational device in the United States.

    For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.

    Forward-Looking Statements

    This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although Allurion believes that it has a reasonable basis for each forward-looking statement contained in this press release, Allurion cautions you that these statements are based on a combination of facts and factors currently known by it and its projections of the future, about which it cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding: the financial outlook for 2024, including driving procedural volume growth, revenue growth, durable pricing, and the impact of cost reduction initiatives on cash burn and operational flexibility; Allurion's ability to complete the AUDACITY trial and support a PMA submission; the impact of investments and initiatives on distribution of the Allurion Program, advancement of its artificial intelligence platform, and improvement of patient outcomes; and the market and demand for our products and weight-loss solutions, including GLP-1 drugs and elective procedures.

    Allurion cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward looking statements are subject to a number of risks and uncertainties, including, among others, general economic, political and business conditions; the ability of Allurion to obtain regulatory approval for, and successfully commercialize, the Allurion Program; the timing of, and results from, its clinical studies and trials; the evolution of the markets in which Allurion competes; and the impact of GLP-1 drugs; the ability of Allurion to maintain its listing on the New York Stock Exchange; the effect of COVID-19, the Russia and Ukraine war and the Israel-Hamas war on Allurion's business and financial results; the outcome of any legal proceedings against Allurion; the risk of economic downturns and a changing regulatory landscape in the highly competitive industry in which Allurion competes; and those factors discussed under the heading "Risk Factors" in the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission ("SEC") on November 14, 2023, and other filings with the SEC. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that Allurion will achieve its objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent Allurion's views as of the date of this press release. Allurion anticipates that subsequent events and developments will cause its views to change. However, while Allurion may elect to update these forward-looking statements at some point in the future, Allurion has no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing Allurion's views as of any date subsequent to the date of this press release.

    ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES UNAUDITED

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    For the Three and Twelve Months Ended December 31, 2023 and 2022

    (dollars in thousands, except per share amounts)

    Three Months Ended December 31,

    Year Ended December 31,

     

     

    2023

     

     

    2022

     

     

    2023

     

     

    2022

     

    Revenue

    $

    8,235

     

    $

    19,184

     

    $

    53,467

     

    $

    64,211

     

    Cost of revenue

     

    1,805

     

     

    3,940

     

     

    11,970

     

     

    13,485

     

    Gross profit

     

    6,430

     

     

    15,244

     

     

    41,497

     

     

    50,726

     

    Operating expenses:

    Sales and marketing

     

    10,730

     

     

    14,941

     

     

    46,857

     

     

    50,405

     

    Research and development

     

    6,071

     

     

    5,732

     

     

    27,694

     

     

    16,966

     

    General and administrative

     

    15,367

     

     

    4,719

     

     

    46,024

     

     

    15,365

     

    Total operating expenses:

     

    32,168

     

     

    25,392

     

     

    120,575

     

     

    82,736

     

    Loss from operations

     

    (25,738

    )

     

    (10,148

    )

     

    (79,078

    )

     

    (32,010

    )

    Other income (expense):

    Interest expense

     

    (3,235

    )

     

    (1,760

    )

     

    (10,566

    )

     

    (4,426

    )

    Changes in fair value of warrants

     

    6,175

     

     

    (922

    )

     

    8,364

     

     

    (821

    )

    Changes in fair value of debt

     

    —

     

     

    —

     

     

    (3,751

    )

     

    —

     

    Changes in fair value of Revenue Interest Financing and PIPE Conversion Option

     

    (152

    )

     

    —

     

     

    (2,192

    )

     

    —

     

    Changes in fair value of earn-out liabilities

     

    4,720

     

     

    —

     

     

    29,050

     

     

    —

     

    Termination of convertible note side letters

     

    —

     

     

    —

     

     

    (17,598

    )

     

    —

     

    Loss on extinguishment of debt

     

    —

     

     

    —

     

     

    (3,929

    )

     

    —

     

    Other income (expense), net

     

    (776

    )

     

    530

     

     

    (643

    )

     

    (344

    )

    Total other income (expense):

     

    6,732

     

     

    (2,152

    )

     

    (1,265

    )

     

    (5,591

    )

    Loss before income taxes

     

    (19,006

    )

     

    (12,300

    )

     

    (80,343

    )

     

    (37,601

    )

    Provision for income taxes

     

    (174

    )

     

    (48

    )

     

    (264

    )

     

    (143

    )

    Net loss

     

    (19,180

    )

     

    (12,348

    )

     

    (80,607

    )

     

    (37,744

    )

    Cumulative undeclared preferred dividends

     

    (0

    )

     

    (732

    )

     

    (1,697

    )

     

    (2,907

    )

    Net loss attributable to common shareholders

    $

    (19,180

    )

    $

    (13,080

    )

    $

    (82,304

    )

    $

    (40,651

    )

    Net loss per share

     

     

     

    Basic and diluted

    $

    (0.40

    )

     

    $

    (0.48

    )

    $

    (2.31

    )

    $

    (1.51

    )

    Weighted-average shares outstanding

     

     

     

    Basic and diluted

     

    47,519,884

     

     

     

    27,006,285

     

     

    35,581,656

     

     

    26,918,484

     

    ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES

    UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

    (dollars in thousands)

     

    December 31,

     

     

    2023

     

     

    2022

     

    Assets

    Current assets:

    Cash and cash equivalents

    $

    38,037

     

    $

    7,685

     

    Accounts receivable, net of allowance of doubtful accounts of $12,671 and $741, respectively

     

    18,194

     

     

    29,346

     

    Inventory, net

     

    6,171

     

     

    3,865

     

    Prepaid expenses and other current assets

     

    2,414

     

     

    2,487

     

    Total current assets

     

    64,816

     

     

    43,383

     

    Property and equipment, net

     

    3,381

     

     

    2,382

     

    Right-of-use asset

     

    3,010

     

     

    2,899

     

    Other long-term assets

     

    505

     

     

    2,706

     

    Total assets

    $

    71,712

     

    $

    51,370

     

    Liabilities and Stockholders' Deficit

    Current liabilities:

    Accounts payable

    $

    10,379

     

    $

    5,809

     

    Current portion of term loan

     

    38,643

     

     

    53,360

     

    Current portion of lease liabilities

     

    908

     

     

    905

     

    Accrued expenses and other current liabilities

     

    15,495

     

     

    15,793

     

    Total current liabilities

     

    65,425

     

     

    75,867

     

    Convertible notes payable, net of discounts

     

    —

     

     

    3,103

     

    Public warrant liabilities

     

    5,943

     

     

    —

     

    Revenue Interest Financing liability

     

    36,200

     

     

    —

     

    Earn-out liabilities

     

    23,990

     

     

    —

     

    Lease liabilities, net of current portion

     

    2,306

     

     

    2,163

     

    Other liabilities

     

    8,335

     

     

    2,551

     

    Total liabilities

     

    142,199

     

     

    83,684

     

    Commitments and Contingencies (Note 16)

    Stockholders' deficit:

    Preferred stock, $0.0001 par value — 100,000,000 shares authorized as of December 31, 2023; and no shares issued and outstanding as of December 31, 2023 and December 31, 2022

     

    —

     

     

    —

     

    Common stock, $0.0001 par value - 1,000,000,000 shares authorized as of December 31, 2023; 47,688,096 and 27,079,856 shares issued and outstanding as of December 31, 2023 and 2022, respectively

     

    5

     

     

    3

     

    Additional paid-in capital

     

    143,007

     

     

    99,875

     

    Accumulated other comprehensive loss

     

    (700

    )

     

    —

     

    Accumulated deficit

     

    (212,799

    )

     

    (132,192

    )

    Total stockholders' deficit

     

    (70,487

    )

     

    (32,314

    )

    Total liabilities and stockholders' deficit

    $

    71,712

     

    $

    51,370

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240321260031/en/

    Get the next $ALUR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ALUR

    DatePrice TargetRatingAnalyst
    11/14/2024Buy → Neutral
    Chardan Capital Markets
    10/2/2024$2.00Buy
    TD Cowen
    9/6/2024$2.00Buy
    ROTH MKM
    2/9/2024$5.00Buy
    Jefferies
    More analyst ratings

    $ALUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Gaur Shantanu bought $24,484 worth of shares (8,000 units at $3.06), increasing direct ownership by 100% to 16,000 units (SEC Form 4)

      4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

      5/21/25 4:15:08 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Gaur Shantanu bought $26,800 worth of shares (8,000 units at $3.35) (SEC Form 4)

      4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

      4/1/25 4:15:07 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care

    $ALUR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Allurion Technologies downgraded by Chardan Capital Markets

      Chardan Capital Markets downgraded Allurion Technologies from Buy to Neutral

      11/14/24 8:29:33 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • TD Cowen initiated coverage on Allurion Technologies with a new price target

      TD Cowen initiated coverage of Allurion Technologies with a rating of Buy and set a new price target of $2.00

      10/2/24 7:13:57 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • ROTH MKM initiated coverage on Allurion Technologies with a new price target

      ROTH MKM initiated coverage of Allurion Technologies with a rating of Buy and set a new price target of $2.00

      9/6/24 7:25:38 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care

    $ALUR
    SEC Filings

    See more
    • SEC Form S-8 filed by Allurion Technologies Inc.

      S-8 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

      6/18/25 5:10:21 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • SEC Form 424B3 filed by Allurion Technologies Inc.

      424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

      5/20/25 5:04:39 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • SEC Form 424B3 filed by Allurion Technologies Inc.

      424B3 - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

      5/20/25 5:02:23 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care

    $ALUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Gaur Shantanu bought $24,484 worth of shares (8,000 units at $3.06), increasing direct ownership by 100% to 16,000 units (SEC Form 4)

      4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

      5/21/25 4:15:08 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Director Rtw Investments, Lp converted options into 1,492,539 shares (SEC Form 4)

      4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

      4/17/25 6:36:58 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Gaur Shantanu bought $26,800 worth of shares (8,000 units at $3.35) (SEC Form 4)

      4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

      4/1/25 4:15:07 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care

    $ALUR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Allurion Announces Submission of PMA to FDA and Additional Analyses From Pivotal AUDACITY Study That Meet Both Endpoints

      Fourth and final module of the PMA submitted in June Supportive analyses included in final module of the PMA meet both of the pre-specified co-primary endpoints in the AUDACITY Study Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced submission of the fourth and final module of the Pre-Market Approval (PMA) application to the Food & Drug Administration (FDA) and additional, supportive analyses from the AUDACITY Study that meet both of the pre-specified co-primary endpoints. Topline results announced previously showed that the AUDACITY Study met its first co-primary endpoint related to responder rate at 48 weeks. Allurion Balloon su

      7/7/25 8:00:00 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Allurion Announces Findings from New Studies on Muscle Mass Maintenance in Nearly 20,000 Patients and Four-Year Weight Loss Outcomes at the 2025 Annual Meeting of the ASMBS

      Findings from two abstracts presented at the American Society for Metabolic & Bariatric Surgery (ASMBS) 2025 Annual Meeting reinforce the role of the AI-powered Allurion Program in delivering metabolically healthy weight loss Real-world experience in nearly 20,000 patients with the Allurion Program confirms significant fat loss while increasing lean body and muscle mass In one of the longest real-world studies of its kind, patients who followed the Allurion Program for four years maintained, on average, 89% of the weight lost during balloon therapy Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today presented two new abstracts at the Amer

      6/17/25 8:00:00 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Allurion to Present at Jefferies Global Healthcare Conference

      Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced that Dr. Shantanu Gaur, Founder and Chief Executive Officer, will present at the upcoming Jefferies Global Healthcare Conference in New York. The live presentation will take place on Wednesday, June 4 at 3:45 p.m. ET. A webcast of the presentation will be available in the Events & Presentations section of Allurion's investor relations website. About Allurion Allurion is a pioneer in metabolically healthy weight loss. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world's first and only swallowable, proced

      5/29/25 4:05:00 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care

    $ALUR
    Leadership Updates

    Live Leadership Updates

    See more
    • Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to Its Board of Directors

      Mr. Johns has worked over two decades bringing leading GLP-1 weight loss drugs and other metabolic drugs to market Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Keith Johns to its Board of Directors effective September 2, 2024. "We are extremely excited to welcome Keith to the Allurion Board of Directors as we look to capitalize on the significant opportunity in front of us within the fast-growing obesity management space," said Dr. Shantanu Gaur, Allurion's Founder and CEO. "I believe having Keith as a sounding board as we leverage the opportunities created by GLP-1s will be a competitive advantage." Omar Ishrak, Al

      9/3/24 8:00:00 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Allurion Announces the Appointment of Adrian Wild as Senior Vice President, International Commercial

      Mr. Wild brings over 20 years of experience building profitable commercial organizations at leading healthcare brands Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Adrian Wild as SVP, International Commercial. Effective August 13, 2024, Mr. Wild assumed the role and will lead the Company's international commercial sales and operations functions. "We are thrilled to welcome Adrian to Allurion and add his expertise to our leadership team as we advance the company toward profitability," said Dr. Shantanu Gaur, Allurion's Founder and CEO. "Adrian joins us at an extremely important time – where the obesity market is expandi

      8/20/24 8:00:00 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Allurion Announces the Appointment of Ojas A. Buch as Chief Operating Officer

      Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced the appointment of Ojas A. Buch as its new Chief Operating Officer. Effective June 3, 2024, Ojas assumed the role of Chief Operating Officer and will lead the company's Research and Development, Manufacturing and Operations, Quality and Regulatory, and Business Development and Innovation functions. He will also play a crucial role in commercial functions while working closely with the Board and Executive Leadership Team. Ojas will provide strategic and execution-focused guidance aimed to help the company achieve major milestones and scale sustainably. With a 25-year track record in the health

      6/5/24 8:00:00 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care

    $ALUR
    Financials

    Live finance-specific insights

    See more

    $ALUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Allurion Reports First Quarter 2025 Financial Results and Provides Business Update

      Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a pioneer in metabolically healthy weight loss, today announced its financial results for the first quarter and provided a business update. Recent Company Highlights and Outlook Maintaining 2025 revenue guidance of approximately $30 million with a reduction of approximately 50% in operating expenses compared to 2024 First quarter revenue of $5.6 million and operating expenses of $11.4 million, a 37% decrease in operating expenses compared to prior year; adjusted operating expenses of $10.1 million, a 45% decrease compared to prior year Net operating loss of $7.3 million, a 36% reduction compared to prior year; adj

      5/14/25 8:00:00 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Allurion to Report First Quarter 2025 Financial Results on May 14, 2025

      Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a company dedicated to ending obesity, today announced that it will report financial results for the first quarter 2025 on Wednesday, May 14, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 646 960 0804 (international) and use Conference ID 1905455. To listen to the conference call via live audio webcast, please visit the Events section of Allurion's Investor Relations website at Allurion - Events & Presentations. A replay of the conferenc

      5/5/25 4:05:00 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

      Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a company dedicated to ending obesity, today announced its financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. Recent Company Highlights and Outlook Reported initial data on the combination of the Allurion Program with low-dose GLP-1s showing optimization of muscle mass and GLP-1 adherence and announced plans to perform additional prospective studies on the combination approach Fourth quarter 2024 revenue of $5.6 million and full year revenue of $32.1 million, consistent with preannouncement on January 14, 2025 Fourth quarter 2024 operating expenses of $19

      3/26/25 8:00:00 AM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Allurion Technologies Inc.

      SC 13G/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

      11/14/24 4:43:43 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Allurion Technologies Inc.

      SC 13G/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

      11/14/24 4:15:52 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Allurion Technologies Inc.

      SC 13D/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

      10/24/24 5:19:39 PM ET
      $ALUR
      Medical/Dental Instruments
      Health Care